Prevalence of carbapenemase-producing enterobacterales in companion animals: a five-year update study. - carbapenem-resistant enterobacterales (CRE) represent one of the most urgent antimicrobial…

Active Cooperative Agreement Awarded

Award ID
U18FD008915
Recipient
Awarding agency
Obligated
$65,000

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 8% complete
Funding agency
Food and Drug Administration Department of Health and Human Services
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

Description

Prevalence of carbapenemase-producing enterobacterales in companion animals: a five-year update study. - carbapenem-resistant enterobacterales (CRE) represent one of the most urgent antimicrobial resistance (AMR) threats to human and animal health. These organisms frequently produce carbapenemase enzymes such as NDM, KPC, and OXA-48 that are often encoded on mobile genetic elements capable of horizontal transfer across bacterial species. Although historically associated with healthcare-associated infections in humans, CRE are increasingly reported in community settings and in non-human hosts. Companion animals may serve as reservoirs or bridging hosts for CRE transmission at the human-animal interface. In 2022, we conducted the first multicenter national surveillance study of carbapenemase-producing CRE (CP-CRE) carriage in U.S. Companion animals through the food and drug administration's veterinary laboratory investigation and response network (VET- lirn). Screening of 2,393 fecal samples from dogs and cats across eight veterinary diagnostic laboratories identified a prevalence of 0.21% and demonstrated the presence of internationally disseminated high-risk clonal lineages closely related to human clinical isolates. Despite the low baseline prevalence, increasing CRE outbreaks in veterinary healthcare environments and rapid expansion of NDM-producing CRE in humans highlight the need for coordinated longitudinal surveillance in companion animals. We hypothesize that CP-CRE prevalence and/or diversity in companion animals has increased over five years, paralleling trends observed in human populations. Aim 1 will determine temporal trends in CP-CRE prevalence among dogs and cats by conducting a prospective multicenter surveillance study across eleven VET-lirn veterinary diagnostic laboratories. Approximately 2,000- 3,000 fecal specimens will be screened using standardized chromogenic culture methods, and prevalence estimates from 2027 will be compared to the 2022 baseline. Aim 2 will characterize all CP-CRE isolates by whole-genome sequencing to identify carbapenemase genes, sequence types, plasmid content, and phylogenetic relatedness to human isolates using the ncbi pathogen detection pipeline. This study will provide the first national longitudinal assessment of CP-CRE carriage in companion animals while expanding CRE screening capacity across the VET-lirn network.

Quick answers

Who received award U18FD008915?

U18FD008915 was awarded to The Trustees Of The University Of Pennsylvania by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award U18FD008915 worth?

$65,000 has been obligated on U18FD008915.

Which agency awarded U18FD008915?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded U18FD008915, with funding from Food and Drug Administration (Department of Health and Human Services).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award